By deadline November 15, Oslo Cancer Cluster received 9 applications for collaborative innovation projects addressing our Immuno-Oncology call on MNOK 1, 2. The applications are now being evaluated and the winners will be announced on Oslo Cancer Cluster`s Christmas Meeting, December 1st.
– We are very pleased about the significant interest and very positive feedback from our members for this funding opportunity. The number and quality of the applications and the breadth of the topics confirms the particular strength in the cancer immunotherapy area in Norway. Based on the feedback from last year’s winners we know that the funding despite the relatively small amount, truly makes a difference and helps to advance the immuno-oncology portfolio within the cluster. Therefore we continuously work to increase the funding available for our members, says Jutta Heix, International Advisor in Oslo Cancer Cluster.
A selection committee with representatives from Oslo Cancer Cluster Incubator, Innovation Norway, with academic, clinical and financing experts as advisors will review the applications. Projects are selected based on their novelty, commercial potential and feasibility. It is important that the funding must make a significant difference for the applicant. This can be in the sense that the project will not be materialized without the funding or that the project will be better (e.g. broader in scope or deeper in its investigation. In addition all applications are reviewed by Innovation Norway to see if they qualify for other funding schemes